Enstilar at a glance

Introducing Enstilar® and why it’s so extraordinary. Enstilar logo

Introducing Enstilar

A once-daily, 4 week topical combination treatment in a foam spray formulation for the treatment of adult plaque psoriasis.1

Enstilar® is highly effective at achieving plaque clearance at week 4

Enstilar® is effective
at achieving plaque
clearance at week 4.2

Enstilar® is easy and convenient to apply once daily

Application
once daily.1

Efficacy

Enstilar® is more effective
than its individual active components
in achieving plaque clearance2

Enstilar® is more effective than its individual active components in achieving plaque clearance

Enstilar® treatment over 4 weeks

Psoriatic skin at baseline
Enstilar treatment after 4 weeks


For illustrative purposes only. Images are of a representative individual psoriasis patient from the PSO-FAST study (DoF: LEO90100 003). Images are of a patient’s hip. Individual results may vary.3

How to use Enstilar®

Shake Enstilar before using
Shake for a few seconds
before use1
Sprayed onto the skin from at least 3 cm distance
Spray on to the skin from
at least 3cm distance1
Applied to the affected areas and rubbed gently into the skin
Apply to the affected areas
and rub gently into the skin1

A guide to prescribing Enstilar®

silhouette of 2 cans of Enstilar
Enstilar table dosage for 4 weeks

As an example, for moderate plaque psoriasis affecting a body surface area of 5-8%, prescribe
2 x 60g cans and refer to the prescribing information for dosing specifics.1


When using Enstilar® the total dose of calcipotriol containing products should not exceed 15g per day and the total body surface area treated should not exceed 30%.1

Return to the treatment overview page
  1. Enstilar Summary of Product Characteristics. 06.10.2020.
  2. Lebwohl M., Tyring S., Bukhalo M. et al. Fixed Combination Aerosol Foam Calcipotriene 0.005% (Cal) Plus Betamethasone Dipropionate 0.064% (BD) is More Efficacious than Calor BD Aerosol Foam Alone for Psoriasis Vulgaris. J Clin Aesthet Dermatol 2016; 9 (2): 34-41.
  3. Leonardi G., Bagel J., Yamauchi P. et al. Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris– a Randomized Phase III Study (PSO-FAST). J Drugs Dermatol. 2015; 14 (12): 1468-1477.
MAT-25025 Oct 2020

Keep in touch with LEO Pharma

New products, new evidence, educational programs, events. Be the first to know about updates from LEO Pharma. Sign up
Holler Box